OOIR: Observatory of International Research

Papers

(The TQCC of Best Practice & Research Clinical Endocrinology & Metabolism is 13. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
Editorial Board	130
Editorial Board	88
Growth hormone replacement in adults with cured acromegaly: Efficacy and safety	81
Recent progress in molecular classification of phaeochromocytoma and paraganglioma	59
Editorial Board	57
The novel concept of “Onco-Immuno-Endocrinology” led to the discovery of new clinical entity “paraneoplastic autoimmune hypophysitis”	56
Gonadectomy in individuals with a difference of sex development – For whom, when, why, and why not?	56
Thiazide-induced hyponatremia	56
Treatment of acromegaly with the nonpeptide, highly selective somatostatin receptor type 2 agonist paltusotine	51
Genetics of pubertal timing	50
The role of androgens in transgender medicine	48
Polygenic risk scores for dyslipidemia and atherosclerotic cardiovascular disease: Progress toward clinical implementation	46
Coronavirus disease 2019 and vitamin D	44
Rare forms of genetic steroidogenic defects affecting the gonads and adrenals	38
Regulation of bone mass: A splendid Orchestra	37
Editorial Board	35
Sexual health and contraception in the menopause journey	35
Immune checkpoint inhibitor-related thyroid dysfunction	34
Editorial Board	31
Optimal surgical approach for digestive neuroendocrine neoplasia primaries: Oncological benefits versus short and long-term complications	31
Remnant lipoprotein particles and cardiovascular disease risk	30
Cardiometabolic outcomes of early onset hypogonadism in males	30
Haematological actions of androgens	29
Editorial Board	29
Medullary thyroid cancer - An update	27

Metabolic complications and their mechanisms in patients with craniopharyngioma	27
Non-oestrogen-based and complementary therapies for menopause	27
Type 1 diabetes related to immune checkpoint inhibitors	27
Epidemiology and risk factors for hypopituitarism due to traumatic brain injury	26
Radioiodine therapy in the different stages of differentiated thyroid cancer	26
Safety of long-term use of daily and long-acting growth hormone in growth hormone-deficient adults on cancer risk	26
The effect of osteoporosis treatment on bone mass	24
Acquired disorders of phosphaturia: Beyond tumor-induced osteomalacia	24
Pathogenic role of Th17 cells in autoimmune thyroid disease and their underlying mechanisms	24
Molecular basis of symptomatic sporadic primary hyperparathyroidism: New frontiers in pathogenesis	24
Onco-immuno-endocrinology: An emerging concept that links tumor, autoimmunity, and endocrine disease	23
Pathophysiology of thyroid-associated orbitopathy	22
Approach to patients with elevated low-density lipoprotein cholesterol levels	22
Immune checkpoint inhibitor-related hypophysitis	22
Editorial Board	21
Hyponatraemic encephalopathy	21
Best practice and research clinical endocrinology and metabolism issue on phaeochromocytomas and paragangliomas	21
Personalized management for phaeochromocytomas and paragangliomas in Latin America: A genetic perspective	21
Editorial Board	20
Localization in primary hyperparathyroidism	20
Best Practice and Research Clinical Endocrinology and Metabolism focusing on Growth Hormone Deficiency in Adults – New Perspectives	20
Editorial Board	19
Pathophysiology and diagnosis of neuroendocrine abnormalities in patients with traumatic brain injury	19
Preconception use of GLP-1 and GLP-1/GIP receptor agonists for obesity treatment	19
History of androgens and androgen action	19
Diagnosis and treatment of hypernatremia	19
Safety of androgen therapy in men with prostate cancer	19
Surgical outcomes in patients with acromegaly: Microscopic vs. endoscopic transsphenoidal surgery	18
Editorial Board	18
Genotype-phenotype correlations in Graves’ disease	17
Diagnostic algorithm of hyponatremia	17
Hyponatremia and bone pathophysiology: An integrated preclinical and clinical perspective	17
Post cancer care in women with an increased risk of malignancy or previous malignancy: The use of hormone replacement therapy and alternative treatments	17
Mortality in craniopharyngiomas: Data from the last two decades	16
Recent advances in algorithms predicting hemodynamic instability undergoing surgery for phaeochromocytoma and paraganglioma	16
Genetics of anti-Müllerian hormone and its signaling pathway	16
Exercise and physical activity in individuals at risk of fracture	15
Best practice & research clinical endocrinology & metabolism focusing on the menopause – Diagnostic and therapeutic strategies	15
COVID-induced thyroid autoimmunity	15
Preface	15
The options for delayed surgery – Is there evidence available for delayed genitoplasty in differences/disorders of sex development?	14
Hormone replacement in disorders of sex development, and long-term effects	14
Care quality improvement in differences of sex development	13
The epidemiology of disorders of sex development	13
“Micromegaly”: Acromegaly with apparently normal GH, an entity on its own?	13
Strategies for improving the knowledge of patients and carers	13
Chemokines in thyroid autoimmunity	13
Anaplastic thyroid cancer: An update	13